- Home
- NGNE vs AII Comparison
NGNE vs AII Comparison
Compare NGNE & AII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- AII
- Stock Information
- Founded
- NGNE 2003
- AII 2006
- Country
- NGNE United States
- AII United States
- Employees
- NGNE N/A
- AII N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- AII Property-Casualty Insurers
- Sector
- NGNE Health Care
- AII Finance
- Exchange
- NGNE Nasdaq
- AII Nasdaq
- Market Cap
- NGNE 325.3M
- AII 370.5M
- IPO Year
- NGNE N/A
- AII 2025
- Fundamental
- Price
- NGNE $18.48
- AII $19.96
- Analyst Decision
- NGNE Strong Buy
- AII Buy
- Analyst Count
- NGNE 7
- AII 4
- Target Price
- NGNE $41.86
- AII $21.67
- AVG Volume (30 Days)
- NGNE 110.1K
- AII 78.8K
- Earning Date
- NGNE 08-11-2025
- AII 08-12-2025
- Dividend Yield
- NGNE N/A
- AII N/A
- EPS Growth
- NGNE N/A
- AII N/A
- EPS
- NGNE N/A
- AII 60.71
- Revenue
- NGNE N/A
- AII $260,047,000.00
- Revenue This Year
- NGNE N/A
- AII $25.82
- Revenue Next Year
- NGNE N/A
- AII $25.78
- P/E Ratio
- NGNE N/A
- AII $0.33
- Revenue Growth
- NGNE N/A
- AII 1.73
- 52 Week Low
- NGNE $6.88
- AII $15.78
- 52 Week High
- NGNE $74.49
- AII $20.32
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- AII N/A
- Support Level
- NGNE $19.59
- AII N/A
- Resistance Level
- NGNE $20.46
- AII N/A
- Average True Range (ATR)
- NGNE 1.23
- AII 0.00
- MACD
- NGNE -0.20
- AII 0.00
- Stochastic Oscillator
- NGNE 13.37
- AII 0.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About AII American Integrity Insurance Group Inc. Common Stock
American Integrity Insurance Group Inc is engaged in the property and casualty insurance business. It provides personal residential property insurance for single-family homeowners and condominium owners as well as coverage for vacant dwellings and investment properties, predominantly in Florida. The Company's property and casualty insurance is currently offered in Florida, South Carolina, and Georgia.